# Trial for MicroPort's Firesorb BVS: FUTURE-III

Study · id `cardio:ct-nct03660202` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03660202](<https://clinicaltrials.gov/study/NCT03660202>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03660202

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT03660202. Allocation not applicable; no masking; primary purpose treatment. Start 2019-01 (anticipated); primary completion 2020-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT03660202, source copy `cardio:ctgov-nct03660202-2018-09-12`, retrieved 2026-10-26)
- Planned start: 2019-01 (anticipated) (ClinicalTrials.gov record NCT03660202, source copy `cardio:ctgov-nct03660202-2018-09-12`, retrieved 2026-10-26)
- Primary completion: 2020-06 (anticipated) (ClinicalTrials.gov record NCT03660202, source copy `cardio:ctgov-nct03660202-2018-09-12`, retrieved 2026-10-26)
- Completion: 2024-06 (anticipated) (ClinicalTrials.gov record NCT03660202, source copy `cardio:ctgov-nct03660202-2018-09-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03660202, source copy `cardio:ctgov-nct03660202-2018-09-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03660202-2018-09-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial for MicroPort's Firesorb BVS: FUTURE-III
- Acronym: FUTURE-III
- Condition: Coronary Artery Disease
- Intervention (Device): Firesorb
- Lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd. (`cardio:org-shanghai-microport-medical-group-co-ltd`)

## Provenance

Content hash: 20e8b203de059a6269de300c112c1d1454add6f1cd2b468f7a56b24a700269f9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
